P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

N. Peled,R. Gillis,S. Kilickap,P. Froesch,S. Orlov,E. Filippova,U. Demirci,P. Christopoulos,I. Cicin,F. Bugdayci Basal,C. Yilmaz, M. Fedor,T. Korkmaz,S. Paydas,O. Gautschi,A. Zirtiloglu,Y. Eralp,H.Y. Cinkir,A. Sezer,M. Erman

Journal of thoracic oncology（2021）

引用 12|浏览15

暂无评分

摘要

Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要